Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Will Inter Partes Review Go Away? Supreme Court Weighs Fate

Nov 18 2017

• By Brenda Sandburg

US-Supreme-Court_V1_1200

Related Content

Allergan May Rue Mohawk Tribe Deal As Court Invalidates Restasis Patents

Oct 17 2017

Novartis Exelon Patch Patent Battle: PTAB Can Disagree With District Court

Apr 06 2017

Ampyra, Patents, And The Perils Of Letting PTAB Get Your Hopes Up

Apr 04 2017

Congress Crafting Bill To Modify Patent Challenges In Wake Of Allergan-Mohawk Deal

Nov 08 2017

What Is Inter Partes Review?

Nov 18 2017

How Comprehensive Do IPR Decisions Have To Be?

Nov 18 2017

White House Credits Eli Lilly With Help In Final Deal On Patent Reform Bill

Sep 15 2011

Supreme Court Upholds IPR Standard Making Patent Invalidation Easier; Will Congress Reverse?

Jun 20 2016

Related Companies

Allergan plc

Eli Lilly and Company

Novartis AG

Noven Pharmaceuticals, Inc.

Acorda Therapeutics, Inc.

AbbVie Inc.

Bristol Myers Squibb Company

Takeda Pharmaceutical Co. Ltd.

Viatris Inc.

Additional Topics

United States Legal Issues Intellectual Property Policy BioPharmaceutical

More from Legal & IP

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window